We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

87 hedge funds and large institutions have $259M invested in iShares US Pharmaceuticals ETF in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

5% more capital invested

Capital invested by funds: $247M → $259M (+$12.5M)

1% more funds holding

Funds holding: 8687 (+1)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

1.73% less ownership

Funds ownership: 111.31%109.58% (-1.7%)

Holders
87
Holders Change
+1
Holders Change %
+1.16%
% of All Funds
2.49%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.06%
New
9
Increased
36
Reduced
25
Closed
8
Calls
Puts
Net Calls
Net Calls Change

IHE Hedge Fund Activity: Q2 2014 in Review

87 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2014, worth a combined $259M — up 5.1% from $247M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IHE positions and 8 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Bank of America, adding an estimated $6.2M. The largest seller was Clark Capital Management Group, exiting entirely with an estimated $7.92M sold.

  • 87 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2014, up from 86 in Q1 2014.
  • Funds reported $259M of iShares US Pharmaceuticals ETF stock for Q2 2014, up 5.1% quarter-over-quarter.
  • 9 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2014 and 8 closed out, a net change of +1 holder.
  • The largest iShares US Pharmaceuticals ETF buyer in Q2 2014 was Bank of America, an estimated $6.2M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q2 2014 was Clark Capital Management Group, an estimated $7.92M sold.

Based on aggregated 13F filings for Q2 2014.